Virus-like Particle Vaccine Containing Toxoplasma gondii Rhoptry Protein 13 Induces Protection against T. gondii ME49 Infection in Mice
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Toxoplasma gondii can infect humans worldwide, causing serious diseases in pregnant women and immunocompromised individuals. T. gondii rhoptry protein 13 (ROP13) is known as one of the key proteins involved in host cell invasion. In this study, we generated virus-like particles (VLPs) vaccine expressing T. gondii rhoptry ROP13 and investigated VLPs vaccine efficacy in mice. Mice immunized with ROP13 VLPs vaccine elicited significantly higher levels of T. gondii-specific IgG, IgG1, IgG2a, and IgA antibody responses following boost immunization and challenge infection, whereas antibody inductions were insignificant upon prime immunization. Differing immunization routes resulted in differing antibody induction, as intranasal immunization (IN) induced greater antibody responses than intramuscular immunization (IM) after boost and challenge infection. IN immunization induced significantly higher levels of IgG and IgA antibody responses from feces, antibody-secreting cells (ASCs), CD4+ T, CD8+ T cells and germinal center B cell responses in the spleen compared to IM immunization. Compared to IM immunization, IN immunization resulted in significantly reduced cyst counts in the brain as well as lesser body weight loss, which contributed to better protection. All of the mice immunized through either route survived, whereas all naïve control mice perished. These results indicate that the ROP13 VLPs vaccine could be a potential vaccine candidate against T. gondii infection.
Abstract
Toxoplasma gondii can infect humans worldwide, causing serious diseases in pregnant women and immunocompromised individuals. T. gondii rhoptry protein 13 (ROP13) is known as one of the key proteins involved in host cell invasion. In this study, we generated virus-like particles (VLPs) vaccine expressing T. gondii rhoptry ROP13 and investigated VLPs vaccine efficacy in mice. Mice immunized with ROP13 VLPs vaccine elicited significantly higher levels of T. gondii-specific IgG, IgG1, IgG2a, and IgA antibody responses following boost immunization and challenge infection, whereas antibody inductions were insignificant upon prime immunization. Differing immunization routes resulted in differing antibody induction, as intranasal immunization (IN) induced greater antibody responses than intramuscular immunization (IM) after boost and challenge infection. IN immunization induced significantly higher levels of IgG and IgA antibody responses from feces, antibody-secreting cells (ASCs), CD4+ T, CD8+ T cells and germinal center B cell responses in the spleen compared to IM immunization. Compared to IM immunization, IN immunization resulted in significantly reduced cyst counts in the brain as well as lesser body weight loss, which contributed to better protection. All of the mice immunized through either route survived, whereas all naïve control mice perished. These results indicate that the ROP13 VLPs vaccine could be a potential vaccine candidate against T. gondii infection.
참고문헌 (12)
- Dubey J, "A review of toxoplasmosis in humans and animals in Ethiopia", Epidemiol Infect, 140, pp.1935~1938 (2012)
- Dubey JP, "Toxoplasmosis of Animals and Humans" (2010), CRC press
- Wang PY, "Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice. Clin", Vaccine Immunol, 19, pp.1916~1920 (2012)
- Masoud Foroutan, "Rhoptry antigens as Toxoplasma gondii vaccine target", Clinical and Experimental Vaccine Research, 8(1), pp.4~26 (2019), 대한백신학회[DOI]
- Lee SH, "Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection", Vaccine, 36, pp.5692~5700 (2018)
- Lee SH, "Protective immunity induced by incorporating multiple antigenic proteins of Toxoplasma gondii into influenza virus-like particles", Front Immunol, 9, pp.3073~ (2018)
- Lee SH, "Protection induced by virus-like particles containing Toxoplasma gondii microneme protein 8 against highly virulent RH strain of Toxoplasma gondii infection", PLoS One, 12, pp.e0175644~ (2017)
- Kang HJ, "Influenza virus-like particles presenting both Toxoplasma gondii ROP4 and ROP13 enhance protection against T. gondii Infection", Pharmaceutics, 11, pp.342~ (2019)
- Yoshida T, "Memory B and memory plasma cells", Immunol Rev, 237, pp.117~139 (2010)
- McHeyzer-Williams LJ, "Antigen-specific memory B cell development", Annu Rev Immunol, 23, pp.487~513 (2005)
- Zhu J, "Differentiation of effector CD4 T cell populations", Annu Rev Immunol, 28, pp.445~489 (2009)
- Holdsworth SR, "Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis", Kidney Int, 55, pp.1198~1216 (1999)